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Summary  
Congenital disorders of glycosylation (CDG) are a heterogeneous and rapidly growing group of 
diseases caused by abnormal glycosylation of proteins and/or lipids. Mutations in genes involved in 
the homeostasis of the endoplasmic reticulum (ER), the Golgi apparatus and the vesicular trafficking 
from the ER to the ER-Golgi intermediate compartment (ERGIC) have been found to be associated 
with CDG. Here, we report a patient with defects in both N- and O-glycosylation combined with a 
delayed vesicular transport in the Golgi apparatus due to mutations in TRAPPC11, a subunit of the 
TRAPPIII complex. TRAPPIII is implicated in the anterograde transport from the ER to the ERGIC 
as well as in the vesicle export from the Golgi apparatus. This report expands the spectrum of genetic 
alterations associated with CDG, providing new insights for the diagnosis and the understanding of 
the physiopathological mechanisms underlying glycosylation disorders. 
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Congenital disorders of glycosylation (CDG) are a heterogeneous and rapidly growing group of 
diseases caused by abnormal glycosylation of proteins and/or lipids. Human CDG include mutations 
in genes involved in the homeostasis of the endoplasmic reticulum (ER) and the Golgi apparatus (GA) 
machinery. CDG patients show a highly heterogeneous clinical phenotype, usually presenting with 
symptoms during the neonatal period or infancy. The course of the disease is generally severe and the 
affected individuals show multiorgan involvement including central nervous system, muscle, liver, 
endocrine system, and coagulation abnormalities (Willett et al., 2013; Freeze et al., 2015). Although 
the altered glycoconjugates are diverse, the diagnosis of these individuals relies on the analysis of the 
glycosylation pattern of serum proteins. Serum transferrin (Tf) is the N-glycoprotein most widely 
used as a tool to detect N-glycosylation defects. In addition, apoCIII analysis, a mucin-type O-
glycoprotein, is also useful to detect O-glycosylation defects. In fact, the aberrant glycosylation 
patterns of these proteins are reliable biomarkers that point to the potential molecular defects 
underlying these diseases: defects of N-glycan assembly (CDG-I), or N-glycan processing (CDG-II), 
or combined defects of N- and O-glycosylation.  
Mutations in genes involved in the homeostasis of the ER and the GA as well as those implicated in 
the vesicle trafficking from the ER to the ER-Golgi intermediate compartment (ERGIC) have been 
found to be associated with CDGs. Indeed, mutations in genes encoding for proteins implicated in 
vesicular Golgi transport, such as the Conserved Oligomeric Golgi (COG) complex subunits  [COG1 
(MIM# 606973), COG2 (MIM# 606974), COG3 (MIM# 606975), COG4 (MIM# 606976), COG5 
(MIM# 606821), COG6 (MIM# 606977), COG7 (MIM# 606978), COG8 (MIM# 606979)] were first 
described as a cause of N-glycosylation type II and O-glycosylation defects (Rosnoblet et al., 
2013).  In recent years, the implementation of next generation sequencing technologies has 
contributed decisively to the description of new CDGs and allowed the identification of new disease-
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causing mutations in genes encoding for proteins implicated in the homeostasis of the Golgi apparatus 
[ATP6V0A2 (MIM# 611716), TMEM165 (MIM# 614726) and TMEM199, (MIM# 616815)].  
Using whole exome sequencing we have identified a CDG patient with a defect in N- and O-
glycosylation combined with a delayed ER to Golgi trafficking due to mutations in TRAPPC11 
(MIM# 614138), a subunit of the TRAPP III complex.  
The patient was a boy from non-consanguineous parents. He was born prematurely at 33 weeks of 
gestation and weighed 1,550g. He presented with hypotonia and a malformation syndrome, with 
microcephaly, retrognatia, campydactilia, high foot arches (pes cavus) and abnormal facies. MRI 
showed brain atrophy. Later on, he developed cholestatic liver, recurrent thrombopenia, nephropathy 
with polyuria, alcalosis, hypernatremia and hypercalciuria, and also osteopathy with osteopenia and 
spontaneous fracture of the tibia. Neurophysiologic studies revealed motor and sensitive peripheral 
neuronopathy and an altered central auditory discrimination. He had recurrent infections, with 
moderate elevation of lactate. He died at 5 months of age.  
Extensive metabolic studies were performed at 4 months of age. Metabolite analysis of plasma and 
urine included amino acids, organic acids, acyl carnitines, free fatty acids, very long chain fatty acids, 
polyunsaturated fatty acids, branched chain fatty acids and sterols. All of them showed normal results. 
Spleen necropsy showed hyperactivities of some lysosomal enzymes (ß-galactosidase, ß-
hexosaminidase and ß-glucuronidase). However, ß-glucurocerebrosidase, galactocerebrosidase, ß-
hexosaminidase, arylsulfatase and N-acetyl-α-galactosaminidase activities were normal in cultured 
fibroblasts.  
Isoelectric focusing of serum Tf showed a glycosylation pattern compatible with CDG type II (Figure 
1A). SELDI-TOF-MS analysis of plasma glycans revealed an abnormal percentage of N-glycan 
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structures compared to control values, with low biantennary and high monoantennary types of glycans 
(Figure 1A). These results were in agreement with those found through the analysis of serum Tf. 
Moreover, the apoCIII glycosylation pattern showed a clear increase of the non-sialylated forms 
(Figure 1A). These observations suggested a combined defect of both N- and O-glycosylation, 
pointing to a defect of the GA function. Therefore, alterations in the subunits of the COG complex 
(COG1-8) were analyzed by western blot and Sanger sequencing but no alterations were found in any 
of the COG subunits (data not shown). Consequently, we performed whole-exome sequencing of the 
patient and his healthy parents (Figure 1B). Since the biochemical phenotype showed a defect in both 
N- and O-glycosylation we filtered for variants of genes encoding for proteins involved in vesicle 
transport as well as in ER and GA functions. We used several filtering strategies and when a recessive 
inheritance pattern was postulated we identified two heterozygous missense mutations in TRAPPC11 
(transport protein particle complex 11). These mutations (c.1141C>G and c.3310A>G) were predicted 
to change proline 381 to alanine (p.Pro381Ala) and threonine 1104 to alanine (p.Thr1104Ala), 
respectively (Figure 1B-C) (GenBank accession number NM_021942.5, nucleotide numbering uses 
+1 as the A of the ATG translation initiation codon in the reference sequence, with the initiation 
codon as codon 1). The c.1141C>G mutation was not annotated in the Exome Aggregation 
Consortium (ExAC) database (LSDB database: 
http://databases.lovd.nl/shared/variants/0000132350). Interestingly, the c.3310A>G substitution 
(rs78663235) has already been reported in the ExAC database with a global allele frequency of 
0.0015, but no homozygous individuals for this change have been reported in the European 
population. Compound heterozygosity was corroborated by the carrier status of the father 
(c.[3310A>G]+[=]) and the mother (c.[1141C>G]+[=]). Results were confirmed by Sanger 
sequencing.  TRAPPC11 encodes for a large protein of 1133 amino acids with two conserved 
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functional regions: the foie gras and gryzum domains (Figure 1C). TRAPPC11 has been described to 
be involved in the assembly and integrity of the TRAPP III complex, which is implicated in the 
anterograde vesicular membrane transport from the ER to the ERGIC as well as in vesicle mediated 
export from the Golgi in mammals (Kim et al., 2006; Scrivens et al., 2011; Brunet et al., 2014). The 
two missense variants identified in our patient correspond to highly conserved amino acids in higher 
eukaryotes, one of them within the foie gras domain (Figure 1C and Supplementary Figure 1). The 
fact that the TRAPPC11 protein levels in fibroblasts of the patient were similar to those seen in 
control cells suggest that these mutations do not compromise the stability of the protein but likely its 
function in the whole complex (Figure 1D). Moreover, the subcellular localization of TRAPPC11 was 
not affected by the mutations reported in this patient, since the protein properly localizes in the GA, as 
expected (Supplementary Figure 2). 
Previous studies identified mutations in TRAPPC11 in three families with a clinical phenotype of 
muscular dystrophy and myopathy with movement disorders and intellectual disability (Bögershausen 
et al., 2013), in another patient with congenital muscular dystrophy with fatty liver and infantile-onset 
cataracts (Liang et al., 2015) and recently in four patients from two unrelated families with triple A 
syndrome (MIM# 231550) (Kohler et al., 2016). However, none of these patients were identified to be 
associated with an abnormal Tf or ApoCIII profile, nor with a CDG syndrome. Immunofluorescence 
studies using antibodies against cis and trans-Golgi markers demonstrated a severe fragmentation of 
the GA in one of the previous reports (Bögershausen et al., 2013). Intriguingly, the morphology of the 
GA was normal in fibroblasts from our patient, as no significant differences were found in the degree 
of Golgi compaction compared to control cells (Figure 1A). As TRAPPC11 is known to be involved 
in ER to Golgi vesicular trafficking, we therefore tested whether this pathway was affected by 
TRAPPC11 mutations. Thus, cells were treated with brefeldin A (BFA), an inhibitor of the ER-Golgi 
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anterograde transport (Jackson et al., 2000). Upon BFA treatment both, patient and control fibroblasts 
showed the complete disassembly of the GA (Figure 1A). Interestingly, after the removal of BFA, a 
significant delay in the reassembly of the GA was observed in patient fibroblasts. These results 
revealed a defect in the anterograde vesicular transport in the TRAPPC11 patient reported here 
(Figure 1A). In addition, the functionality of the retrograde Golgi vesicle transport was also assessed 
in our patient but no abnormalities were observed (data not shown). These results are in agreement 
with the vesicular stomatitis virus (VSV-G) trafficking defect observed in the patients reported by 
Bögershausen et al (2013).  
Previous studies in mammalian cellular models have demonstrated that the presence of TRAPPC11 is 
critical to keep the integrity of the TRAPP III complex, as its total depletion resulted in strong 
fragmentation of both, the Golgi apparatus and the ERGIC (Scrivens et al., 2011. However, in our 
patient an alteration in the GA dynamics was only detected upon BFA treatment. We hypothesise that 
the normal expression levels and the correct subcellular localization of the mutant TRAPPC11 protein 
of our patient may be sufficient to maintain, at least partially, the integrity of the TRAPP III complex 
and, subsequently, the structure of the Golgi apparatus regardless of the evident ER-Golgi anterograde 
transport defect (Figure 1D, Supplementary Figure 2A). However, the question whether the slight 
TRAPPC11 alteration resulted in such a severe clinical phenotype remains unanswered. 
The main biochemical feature of the TRAPPC11 patient reported here is the abnormal N and O-
glycosylation pattern detected in plasma Tf and apoCIII proteins (Figure 1A). This finding is novel 
and provides a reliable biochemical marker for the diagnosis of this disorder. Moreover, our 
observations are supported by a recently published study using a zebrafish model carrying a mutation 
in the TRAPPC11 foie gras domain (DeRossi et al., 2016). In that work, the authors demonstrated that 
lipid-linked oligosaccharides were decreased in the TRAPPC11 mutant animals and hypothesised that 
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TRAPPC11 deficiency causes a dysfunction in the synthesis of dolichol, a substrate required for the 
protein N-glycosylation, and the induction of the unfolded-protein response (UPR). Moreover, HeLa 
cells treated with siRNA against TRAPPC11 showed an abnormal accumulation of the non-
glycosylated form of the signal sequence receptor α (SSR1), a protein marker with two glycosylation 
sites not processed in the GA (DeRossi et al., 2016). These results were unexpected as they could not 
be explained by the already known role of TRAPPC11 in trafficking. Interestingly, the 
downregulation of other TRAPP III subunits showed no defects in protein glycosylation. In fact, it is 
known that several TRAPP III complex subunits have additional functions other than vesicle 
trafficking (Gedeon et al., 1999; Milev et al., 2015). Thus, in addition to the role in maintaining 
TRAPP III complex integrity, TRAPPC11 may also be involved in the regulation of N-linked 
glycosylation and, as a consequence, protein glycosylation might be altered in patients with 
TRAPPC11 mutations. To this effect, two recent reports showed that LAMP1 protein could be either 
hypo- or hyper- glysosylated in TRAPPC11 patients. These apparently controversial results could 
reflect, in fact, a membrane trafficking defect caused by TRAPC11 deficiency.  
The patient reported here showed a constitutive activation of the UPR, mimicking the observations 
made in TRAPPC11-deficient cellular and animal models (Figure 2) (DeRossi et al., 2016). 
Moreover, our results suggested that the N-glycosylation defects observed in our patient cannot only 
be attributed to a dysfunction in the dolichol synthesis pathway, as previously hypothesised (DeRossi 
et al., 2016), since dolichol levels in liver necropsy from our patient were similar to those found in age 
matched controls (Supplementary Figure 3). Therefore, the strong UPR activation observed in our 
patient suggests that the glycosylation defects may result in the accumulation of unfolded/misfolded 
proteins in the ER regardless of the dolichol levels. Altogether these observations point to a 
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widespread role of TRAPPC11 in the molecular and cellular pathways involved in protein 
glycosylation and Golgi vesicular transport. 
In summary, this report expands the spectrum of genetic alterations associated with CDG, providing 
new insights into the diagnosis as well as for the understanding of the physiopathological mechanisms 
underlying vesicle trafficking defects and glycosylation disorders. We highlight the importance of an 
accurate biochemical characterization to direct the genetic data analysis when using next generation 
sequencing tools. Our study demonstrates that TRAPPC11 deficiency could lead to a disorder 
targeting the GA function which might be readily identified by routine screening for abnormal 
glycosylation patterns of plasma proteins.  
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FIGURE LEGENDS 
Figure 1. Identification of TRAPPC11 mutations in a patient with defects in N- and O-
glycosylation. (A) Analysis of plasma glycans from the TRAPPC11 patient by SELDI-TOF-MS in 
negative ion mode (left panel) together with Transferrin and Apo CIII glycosylation patterns (right 
panel) of a control individual (C), a CDG type I patient (CDG-I) and the TRAPPC11 patient (P).  
SELDI-TOF-MS showed an altered percentage of N-glycan structures compared to control values. 
The major abnormal species corresponds to biantennary N-linked glycan that lacks a single sialic acid 
(SA) residue and a single galactose (Gal) residue. Relative amounts are presented as a percentage of 
the total identified N-linked glycan structures compared to control values. n.d.: not detectable; SA: 
sialic acid; Gal: galactose; GlcNac: N-Acetylglucosamine. (B) Exome data analysis and filtering steps 
leading to the identification of TRAPPC11 as a putative genetic cause of the disease. (C) Human 
TRAPPC11 protein scheme showing the position of the identified mutations. (D) Western blot 
analysis of TRAPPC11 in patient fibroblasts (P) and in a control individual (C). SDHA was used as 
loading control.  
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Figure 2. ER-to-Golgi anterograde membrane flow is defective in the TRAPPC11 patient.  (A) 
Fibroblasts from the TRAPPC11 patient and from a control individual were treated with brefaldin A 
(BFA) for 15 min to block ER-Golgi anterograde transport. (B) After BFA removal, the percentage of 
cells with assembled Golgi apparatus together with the (C) Golgi compactation index (calculated as 
4π*Σ(areas)/Σ(perimeter)2) were analyzed at different time points, using the Fiji image processing 
package (Schindelin  et al., 2012). Antibody against GM130 was used to stain the Golgi apparatus. 
(D) Fibroblasts from TRAPPC11 patient and from a control individual were analyzed by qPCR for 
expression of four UPR (unfolded protein response) effectors and target genes using the comparative 
Ct method. GAPDH gene was used as an internal control. Results are expressed in relative units 
(RU),* p<0.05. 
 
 
